Lyka Labs Limited released its earnings results on Nov 12, 2025. The company reported -₹0.941 earnings per share for the quarter, missing the consensus estimate of N/A by -₹0.941.

Is Lyka Labs Limited overvalued?

According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lyka Labs Limited pay dividends?

Lyka Labs Limited does not currently pay dividends.

What is Lyka Labs Limited’s EPS estimate?

Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lyka Labs Limited have?

Lyka Labs Limited has 35,690,000 shares outstanding.

What happened to Lyka Labs Limited’s price movement after its last earnings report?

Lyka Labs Limited reported an EPS of -₹0.941 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.131%.

Which hedge fund is a major shareholder of Lyka Labs Limited?

Currently, no hedge funds are holding shares in IN:LYKALABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lyka Labs Limited

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.